Search

Author/Creator Bhomia, Vinay

1. Corrigendum to "Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study" [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]. (August 2021)

Authors:
Pandit, Anuja; Bhalani, Nirav; Bhushan, B.L. Shashi; Koradia, Parshottam; Gargiya, Shweta; Bhomia, Vinay; Kansagra, Kevinkumar
Journal:
International journal of infectious diseases
Issue:
Volume 109(2021)
Page Start:
322
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. (October 2021)

Authors:
Bhushan B L, Shashi; Wanve, Sunil; Koradia, Parshottam; Bhomia, Vinay; Soni, Pravin; Chakraborty, Sisir; Khobragade, Akash; Joshi, Shashank; Mendiratta, Sanjeev Kumar; Kansagra, Kevin Kumar; Parihar, Anurag; Sharma, Sunil; Patel, Jatin
Journal:
International journal of infectious diseases
Issue:
Volume 111(2021)
Page Start:
281
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study. Issue 11 (2nd November 2021)

Authors:
H S, Ravish; Khobragade, Akash; Satapathy, Durga; Gupta, Monica; Kumar, Surendra; Bhomia, Vinay; V, Ramasubramanian; Desai, Maharshi; Agrawal, Ashok Dilipkumar
Journal:
Human vaccines & immunotherapeutics
Issue:
Volume 17:Issue 11(2021)
Page Start:
4239
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗